What is Celcuity?
Headquartered in Minneapolis, Celcuity operates at the intersection of molecularly targeted therapies and companion diagnostics. The company's core innovation, the CELsignia platform, distinguishes itself by analyzing live patient tumor cells to identify specific patient populations that may derive therapeutic benefit from existing, approved treatments. This dual-pronged strategy—in-licensing targeted therapies while simultaneously developing the diagnostic tools to identify the right candidates—positions Celcuity as a high-potential player in the precision oncology market. By focusing on the underlying drivers of cancer, the firm aims to reduce the trial-and-error nature of traditional cancer treatment, offering a more personalized and effective therapeutic pathway for patients facing complex diagnoses.
How much funding has Celcuity raised?
Celcuity has raised a total of $117.5M across 6 funding rounds:
Multiple Rounds
$31.1M
Debt
$350K
Stock Offering
$24M
Debt
$62M
Debt (2017): $5.8M, investors not publicly disclosed
Debt (2017): $2.6M, investors not publicly disclosed
Stock Issuance/Offering (2017): $22.8M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Stock Issuance/Offering (2021): $24M backed by Craig-Hallum Capital Group
Debt (2024): $62M with participation from Oxford Finance
Key Investors in Celcuity
Oxford Finance
Oxford Finance is a specialty finance firm providing flexible capital solutions tailored to the unique needs of healthcare and life sciences companies.
Craig-Hallum Capital Group
Craig-Hallum Capital Group is an investment banking firm that provides comprehensive financial advisory and capital raising services to growth-oriented companies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Celcuity?
With the infusion of capital from this major enterprise-level funding, Celcuity is well-positioned to scale its clinical development efforts. The strategic allocation of these funds will likely prioritize the advancement of its lead therapeutic candidates and the further validation of the CELsignia platform across diverse oncology indications. As the company transitions through its clinical-stage lifecycle, the focus will shift toward regulatory milestones and potential commercialization partnerships. Investors are closely monitoring the firm's ability to translate its diagnostic insights into tangible clinical success, which remains the primary catalyst for long-term value creation in the biotechnology space. The company's disciplined approach to capital management, combined with its robust intellectual property, suggests a clear path toward addressing significant unmet needs in the global cancer treatment market.
See full Celcuity company page
